Abstract
Phosphatase and tensin homologs deleted on chromosome 10 (PTEN) is a potent tumor suppressor and often dysregulated in cancers. Cellular PTEN activity is restrained by the oxidation of active-site cysteine by reactive oxygen species (ROS). Recovery of its enzymatic activity predominantly depends on the availability of cellular thioredoxin (Trx) and peroxiredoxins (Prx), both are important players in cell signaling. Trx and Prx undergo redox-dependent conformational changes through the oxidation of cysteine residues at their active sites. Their dynamics are essential for protein functionality and regulation. In this review, we summarized the recent advances regarding the redox regulation of PTEN, with a specific focus on our current state-of-the-art understanding of the redox regulation of PTEN. We also proposed a tight association of the redox regulation of PTEN with Trx dimerization and Prx hyperoxidation, providing guidance for the identification of novel therapeutic targets.
Keywords: PTEN, Redox regulation, Peroxides, Trx dimerization, Prx dimerization, Prx hyperoxidation
1. Introduction
Reactive oxygen species (ROS) are inevitably generated during aerobic and anaerobic metabolism and have detrimental effects on cellular biomolecules under pathological conditions [1]. Increasing evidence has indicated that ROS, such as H2O2, are produced and employed in physiological settings to serve as important signaling messengers for coordinating a variety of physiological functions, including proliferation, differentiation, apoptosis, signal transduction, and other critical events [[2], [3], [4], [5]]. To function as signaling messengers, these reactive molecules mainly trigger reversible oxidative post-translational modifications (PTMs) of reactive cysteine residues in regulatory proteins [6]. Because of the lack of enzymes to remove hydroxyl radicals and reactive aldehydes, their aggressive reactivity leads to the irreversible oxidation or degradation of functional proteins [7,8], a mechanism underlying various disorders and pathologies, such as diabetes, obesity, and cancer [9,10].
Signaling through PI3K/AKT is pivotal to cell growth and survival. The interaction of growth factors with receptor tyrosine kinases (RTK) typically activates PI3K. It has been shown that external stimuli, such as insulin, cytokines, neurotransmitters, peptide growth factors, and hormones, can activate the PI3K pathway, which results in ROS generation [5,[11], [12], [13]]. Upon the activation of cells by growth stimuli, classic PI3K family members catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), a potent activator of 3-phosphoinositide-dependent kinase (PDK) and AKT. PTEN is a nonredundant, plasma-membrane lipid phosphatase that can antagonize PI3K by dephosphorylating PIP3 at position D3 to generate PIP2. Numerous studies have demonstrated that the catalytic activity of PTEN is modulated by ROS, subsequently resulting in its catalytic inhibition [14,15]. Therefore, the oxidative modification of PTEN contributes to augmenting PIP3 levels, resulting in the activation of the PI3K/AKT signaling pathway and protecting cells from oxidative stress-induced cell death.
Endogenous antioxidants, such as thioredoxins (Trxs) and peroxiredoxins (Prxs), can modulate ROS levels and intracellular redox state. Thus, they have become targets for redox modifications [16]. Trxs can catalyze the reversible reduction of protein disulfide bonds using redox-active cysteine residues in their active site. Prxs are a family of thiol-dependent antioxidants that can scavenge cytosolic or mitochondrial peroxides. Trx and Prx undergo redox-dependent modifications of catalytic amino acids that can affect protein functionality or impact subcellular protein targeting, protein-protein interactions, or protein stability. In this review, we focused on recent achievements and novel insights into the redox regulation of PTEN induced by peroxides. We also discussed the tight connection of PTEN redox regulation with Trx dimerization and Prx hyperoxidation.
2. Cellular functions of PTEN
PTEN, a redox-sensitive dual-specificity protein and lipid phosphatase, was first identified as a tumor suppressor. It is frequently lost in a variety of human tumors of numerous tissues including the brain, breast, and prostate [17]. PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Even a subtle decrease in PTEN level and/or activity can result in cancer susceptibility and favor tumor progression. The crystal structure of human PTEN protein has revealed an N-terminal PIP2-binding/phosphatase domain (PBD), a lipid-binding C2 domain, a C-terminal tail domain (C-tail), and a class I PDZ (PSD-95, DLG1, and ZO-1) binding domain. PTEN is known as a lipid phosphatase for PIP3. PIP3 functions as a secondary messenger that regulates cell polarity and migration [18]. PTEN can then coordinate cell proliferation, growth, survival, and metabolism by negatively regulating the PI3K/AKT/mTOR signaling pathway [[19], [20], [21]]. Additionally, it has been reported that PTEN can directly dephosphorylate residues on itself and several other protein substrates, including phosphoprotein focal adhesion kinase 1 (FAK), Shc, cAMP-responsive element-binding protein 1 (CREB1), insulin receptor substrate 1 IRS1, Dishevelled (DVL), and others to exert its tumor suppressive functions [[22], [23], [24], [25], [26], [27]]. Molecular details regarding PTEN in the regulation of cellular signaling pathways (Fig. 1) and its role in human diseases have been described in several reviews [[28], [29], [30]].
A growing body of evidence has indicated that PTEN can exert part of its tumor suppressive functions by controlling cell migration, spreading, focal adhesions, and genomic stability, independent of its phosphatase activities [23,28,31]. For instance, microspherule protein 1 (MSP58)-mediated cellular transformation is inhibited by its physical interaction with the C-terminal domain of PTEN [32]. A recent study showed that cytosolic PTEN could suppress CHD-1 induced trimethyl lysine-4 histone H3 modification by stimulating chromodomain-helicase-DNA-binding protein 1 (CHD1) proteasomal degradation, leading to the transcriptional activation of the TNF/NF-κB pathway [33]. Accordingly, in vivo genetic analyses in mouse models have revealed that PTEN loss is not synonymous with AKT overexpression [34].
Recent studies revealed the existence of translational isoforms of PTEN, PTEN-Long (PTEN-L) and PTEN-β. Like canonical PTEN, PTEN-L is a membrane-permeable lipid phosphatase that is secreted from cells and can be taken up by other cells directly. PTEN-L, also localized in the mitochondria, can regulate mitochondrial functions and energy production by associating with canonical PTEN to increase PTEN-induced putative kinase 1 (PINK1) expression [35,36]. PTEN-β localizes in the nucleolus and negatively regulates ribosomal DNA transcription and ribosomal biogenesis by physically interacting with and dephosphorylating nucleolin [37]. With a high sequence homology to canonical PTEN, PTEN-L, and PTEN-β may be modulated by the same or similar mechanisms.
Disruptions in the regulation of PTEN by a range of molecular mechanisms can generate various dysfunctional PTEN species and/or a spectrum of PTEN levels that can variously contribute to the pathogenesis of inherited syndromes, including Cowden disease, Lhermitte-Duclos syndrome, Bannayan-Zonana Syndrome [38], cancers, and other diseases. These molecular mechanisms include the epigenetic loss and mutation of PTEN; transcriptional regulations; post-transcriptional regulation, including microRNA, the disruption of competitive endogenous RNA (ceRNA) networks, and long non-coding RNAs; post-translational modifications; and the aberrant localization of PTEN. PTEN function is also finely regulated through protein-protein interactions [28,39]. More recently, evidence has shown that PTEN is capable of forming dimers, which has been proven to be a novel mechanism for its functional regulation [40]. The following sections highlight our current understanding of the redox regulation of PTEN in cell biology.
3. Redox regulation of PTEN by peroxides, thioredoxin, and peroxiredoxin
3.1. Oxidative inactivation of PTEN by H2O2
PTEN is sensitive to oxidation because it contains nucleophilic cysteine residues in the active site. It has been reported that the catalytic activity of PTEN is fine-tuned by the exposure to oxidizing agents in vitro or oxidative stress conditions in cells. The essential active Cys124 residue of human PTEN, surrounded by three basic amino acid residues in the active site pocket, is readily oxidized by forming an intramolecular disulfide with Cys71 [15], resulting in the inhibition of its phosphatase activity. Importantly, H2O2-mediated PTEN oxidation is reversible, which is predominantly reduced by thioredoxin. Conversely, cellular PTEN activity can be protected by the presence of ROS scavengers [41]. We have designed a convenient approach to monitor intra-PTEN disulfide using a mobility shift assay [15,42] (Fig. 2). In this procedure, all free cellular thiols and selenols of proteins are first blocked by alkylation with N-ethylmaleimide (NEM) and the alkylated PTEN confers a higher molecular weight. The proteins were then separated under non-reducing conditions in the presence of sodium dodecyl sulfate (SDS) and subjected to immunoblots using antibodies to PTEN. Differences in molecular weight and conformational structure, the oxidized and reduced forms of PTEN can then be visualized [15]. Treatment of HeLa cells with H2O2 resulted in PTEN oxidation in a time-dependent manner, with the maximal oxidation after 10 min of exposure. The oxidized PTEN was then converted to the reduced form, mostly after 120 min of exposure (Fig. 3). This clearly indicates that the oxidation reaction in the cells was reversible. In cells exposed to H2O2, the augmented oxidation of PTEN was accompanied by an elevation in the amount of cellular PIP3 [15] and the downstream activation of AKT through its phosphorylation, both on Ser473 (pAktSer473) and Thr308 (pAktThr308) (Figs. 3 and 4A). Phosphorylation of both Thr308 and Ser473 residues is required for the full activation of Akt. H2O2-dependent increases in PIP3 abundance and Akt activity were correlated with the oxidative inactivation of PTEN in PTEN-expressing glioma cells, but not in PTEN-null glioma cells, further supporting the notion that oxidative stress regulates PI3K-dependent signaling through the oxidative inhibition of PTEN [[43], [44], [45]].
Catalytic activity of PTEN is modulated by thioredoxin. Oxidation-driven PTEN inactivation can be reversed by cellular reducing systems, among which the thioredoxin (Trx) system plays a major role. Trx plays an important role in PTEN activation after H2O2 treatment. It has been demonstrated that Trx is even more efficient than glutathione or glutaredoxin in the reduction of oxidized PTEN [15]. Trx is a ubiquitous protein presents in all species from archaebacteria to human. Functions of Trx have been subjected in many investigations [46]. Primarily, the reduced form of Trx serves as a general protein thiol-disulfide oxidoreductase. The evolutionarily conserved Trp-Cys32-Gly-Pro-Cys35 catalytic center provides sulfhydryls involved in Trx-dependent reducing activity. The N-terminal cysteine of the reduced form Trx initiates a nucleophilic attack on the target protein disulfide and forms a transient mixed disulfide which is subsequently attacked by the C-terminal cysteine of Trx to generate the reduced target protein and oxidized Trx with a disulfide bond. Such oxidized Trx is recycled by Trx reductase (TrxR), which utilizes NADPH as an electron donor [47]. Thus, the Trx system is comprised of Trx, selenoenzyme TrxR, and NADPH [48,49], known to have pivotal roles in the regulation of redox signaling via maintaining the thiol-related redox status balance.
Previous studies have revealed that E. coli and human Trxs act as monomers [[50], [51], [52]]. It has been observed that Trxs derived from vertebrates are more susceptible to oxidation that forms dimers or oligomers via Cys residues [50]. Except for the formation of an active Cys32-Cys35 disulfide, a non-active Cys62-Cys69 disulfide bond, dimers, and multimers are also formed under long exposure to air or high levels of H2O2 and diamide [50,51,53,54]. Crystallographic studies have revealed that dimerization through an intermolecular disulfide bond between Cys73 and Cys73’ of two monomers renders Trx unable to carry out its redox activity compared to the crystallized Trx-TrxR complex [50,55]. The homodimerization of Trx started to accumulate 5 min after H2O2 treatment and lasted until 60 min of incubation in HeLa extracts (Fig. 4B). However, the Trx dimer disappeared after 120 min of incubation, showing a similar trend in the reduction kinetics of H2O2-oxidized PTEN. This suggests the H2O2-induced production of Trx dimers in response to elevated levels of oxidized PTEN. Dimeric Trx has long been considered as a potential cellular regulatory redox signaling molecule that might be a possible target for the development of anticancer drugs [56]. Our studies have reported that cellular Trx is one of the targets of organic hydroperoxides that can induce Trx dimerization and oligomerization, causing the irreversible oxidation of PTEN [49,57].
Trx is overexpressed in many human cancers. It is associated with increased tumor cell proliferation, inhibited apoptosis, and decreased patient survival [58,59]. It has been previously reported that increased levels of Trx1 can bind to PTEN in a redox-dependent manner to inhibit its PtdIns-3-phosphatase activity, resulting in increased Akt activation in cells [60]. The interaction between Trx-1 and PTEN occurs through a disulfide bond between the active site Cys32 of Trx-1 and Cys212 of PTEN, inhibiting PTEN's lipid phosphatase activity and increasing tumorigenesis [60]. This provides an additional mechanism for tumorigenesis with a loss of PTEN activity. However, the inactivation of PTEN by Trx can be reversed in the presence of thioredoxin-interacting protein (Txnip). Upon Txnip interaction with Trx through a disulfide bond between Cys247 of Txnip and C32 of Trx, Trx is no longer able to bind and allow for reactivate PTEN [61].
Catalytic activity of PTEN is modulated by peroxiredoxin. Peroxiredoxins (Prxs) are a ubiquitously expressed family of small non‐seleno peroxidases (22–27 kDa) that can catalyze reduction of H2O2, organic hydroperoxides, and peroxynitrite using reducing equivalents provided by thiol-containing proteins [62]. Mammalian cells possess six isoforms of Prxs. They can be classified into three subgroups: four 2-Cys Prx isoforms (Prx1-4), one atypical 2-Cys Prx isoform (Prx5), and one 1-Cys Prx isoform (Prx6) [62]. Although these six mammalian Prx isoforms have different individual functions in cellular redox regulation and antioxidant protection, they all enable to regulate intracellular H2O2 levels by catalyzing peroxide reduction for signaling and metabolism [63]. All mammalian Prx enzymes are homodimers arranged in a head-to-tail orientation. They contain a conserved cysteine residue in the N-terminal region that is the primary site of the oxidation of H2O2. In the catalytic cycle of 2-Cys Prx proteins, the conserved CP-SH (Cys51 in Prx1) is selectively oxidized to CP-SOH intermediate at low levels of H2O2. After reacting with the C-terminal-conserved CR-SH (Cys172 in Prx1) of the other subunit in the homodimer, an intermolecular disulfide is generated. Ultimately, it is specifically reduced by Trx [62,64]. Under normal cellular homeostasis with low H2O2, rather than displaying peroxidase activity, predominantly low-molecular weight oligomeric 2-Cys Prxs can also protect proteins from degradation. With higher doses of H2O2, CP-SOH generated as an intermediate during catalysis, occasionally undergoes further oxidation to CP-SO2H catalysis in the presence of Trx, resulting in the inactivation of its peroxidase activity. The generated CP-SO2H can be reduced back to thiol by sulfiredoxin (Srx) [65,66]. However, further oxidation to CP-SO3H is irreversible, resulting in Prx degradation [65]. Recently, it has been reported that when Cys51 in Prx1 was in an overoxidized form due to oxidative stress or heat shock stress, the formation of high molecular weight complexes was favored [67]. The structural change from low molecular weight oligomers to high molecular weight complexes is accompanied by a functional change from peroxidase to molecular chaperone activity [68,69]. The peroxidase function of Prx can be regulated by various post-translational modifications, including phosphorylation, lysine acetylation, glutathionylation, nitrosylation, and thiol oxidation [[70], [71], [72], [73], [74]].
It has been reported that Prx1 can protect and promote PTEN tumor suppressive function by interacting with PTEN and protecting disulfide bond formation under mild oxidative stress [75]. The lipid phosphatase activity of PTEN was fully preserved by Prx1 in cells under low concentrations of H2O2 (25 μM), where Prx1 was found to interact with PTEN. However, under higher concentrations of H2O2 (500 μM), Prx1 was irreversibly hyperoxidized and dissociated from PTEN [75]. Prx1 preserved PTEN lipid phosphatase activity under oxidative stress at a 1:1 (mol:mol) ratio of Prx1 and PTEN, and could not be further enhanced by excess Prx1, indicating that Prx1 most likely interacts with PTEN as a monomer [75]. Mutational analysis and computational analysis suggested that Prx1 interacts within the C2 domain of PTEN (aa 186–274) and PTEN with the N-terminal of Prx1 (aa 1–21) and the C- terminal of Prx1 (aa 183–199) [75]. Hyperoxidized Prx was observed when cells were exposed to H2O2 for various times using an antibody specific against cysteine sulfinic acids (Fig. 5A). The basal Prx1 dimer was readily observed in H2O2-untreated HeLa cells because Prxs are predominantly obligate dimers at the time of lysis in the absence of NEM. Prx1 hyperoxidation was increased maximally after 5 min of exposure and then decreased progressively over time (Fig. 5B). In addition, augmentation with oxidized PTEN induced by H2O2 showed kinetics similar to H2O2-induced Prx1 hyperoxidation (Fig. 5C). The temporary inhibition of Prx by hyperoxidation impaired H2O2-scavenging activity.
Inactivated Trx dimerization resulted in a delay in the reduction of PTEN and Prx1. However, whether Prx1 reduced the H2O2-induced intramolecular disulfide bond in PTEN is still unclear. Consequently, the redox regulation of PTEN by H2O2 is mediated through Trx and Prx systems in cell signaling.
3.2. Oxidative inactivation of PTEN by organic hydroperoxides
Organic peroxides and hydroperoxides are tumor promoters [76]. The tumor promoting activity of organic hydroperoxides involves in generation of free radical derivatives [[77], [78], [79]]. Cumene hydroperoxide (CuHP) is a stable organic hydroperoxide with oxidizing capabilities [80]. CuHP can induce lipid peroxidation by reacting with adjacent fatty acid side-chains in the presence of transition metal, resulting in continuous generation of lipid hydroperoxides via chain reactions [81,82]. These lipid hydroperoxides, in turn, can generate several ROS, such as alkoxyl and peroxyl radicals in vitro and in vivo, thereby exerting various types of oxidative damage, including lipid peroxidation, protein modification, and DNA damage [80,83,84]. Tert-butyl hydroperoxide (t-BHP) is extensively metabolized in target issues to form several free radical intermediates, including phenoxyl, peroxyl, alkoxyl, and alkyl radical derivatives in murine keratinocytes [80], hemoglobin-thiyl and methyl radicals in rat liver stomach [85]. The cytotoxic effects of t-BHP are involved in glutathione depletion [86], hemoglobin oxidative denaturation, hemolysis and erythrocyte membrane lipid peroxidation [87,88], inner mitochondrial membrane permeabilization [89], DNA single strand breakage [90,91], and apoptosis [76]. Stimulation of HeLa cells or recombinant PTEN with either CuHP or t-BHP resulted in PTEN oxidation by forming an intramolecular disulfide between Cys124 and Cys71 in time- and concentration-dependent manners [49,57]. However, these organic hydroperoxides-mediated cellular PTEN oxidation was not reversible, because the cellular Trx was inactivated by dimerization [49,57]. In addition, the ablation of Prx enhanced CuHP-induced PTEN oxidation in MEF cells [49]. Overall, these results imply that PTEN is an important physiological target for organic peroxide-mediated redox signaling. Its irreversible oxidation could play a key role in organic peroxide-induced tumorigenesis.
3.3. Oxidative inactivation of PTEN by lipid peroxide
Lipoxygenases (LOX) can catalyze the production of hydroperoxyeicosatetraenoic acid (HpETE) from arachidonic acid (AA). 15-LOX can metabolize AA to form 15(s)-hydroperoxyeicosatetraenoic acid (15s-HpETE), the oxidative precursor of 15-hydroxyeicosatetraenoic acid (15s-HETE). Human 15-LOX has two isoforms, 15-LOX-1 and 15-LOX-2. 15-LOX-1 is a dual-specificity enzyme that metabolizes AA, principally to 15s-HpETE, and to far smaller amounts of 12s-HpETE. 15-LOX-2 can metabolize AA to 15s-HpETE. It has little or no ability to metabolize AA to 12s-HpETE. These HpETEs are subsequently reduced and transformed to produce eicosanoids known to be important signaling molecules in immune responses and other physiological processes. Increased levels of lipid peroxides have been linked to the pathogenesis of a variety of human diseases, including neurodegeneration, atherosclerosis, type Ⅱ diabetes, metabolic disorders, solid tumors, and hematologic malignancies, through cellular oxidative damage [[92], [93], [94], [95]]. The ability of lipid peroxides to oxidize PTPs has been reported [96]. PTEN oxidation by unidentified AA metabolites has also been shown [97]. Both 15s-HpETE [98] and 12s-HpETE (Fig. 6) resulted in PTEN oxidation in MEF cells, and Prx III deletion aggravated the 12/15s-HpETE-induced PTEN oxidation in MEF cells. 15s-HpETE-mediated cellular PTEN oxidation was identical to that of H2O2, indicating that an intramolecular disulfide bond between Cys124 and Cys71 was formed [98]. However, 15s-HETE was unable to induce PTEN oxidation in MEF cells [98].
3.4. S-nitrosylation of PTEN by nitric oxide
PTEN is also modified by S-nitrosylation [[99], [100], [101]], a covalent modification of cysteine residues by nitric oxide (NO), which is another crucial redox mechanism that regulates PTEN activity. S-nitrosylation and H2O2-mediated oxidation occur on distinct Cys residues of PTEN. A recent study has shown thatNO can induce PTEN S-nitrosylation on Cys83, leading to the suppression of lipid phosphatase activity of PTEN and induction of PTEN protein degradation via the ubiquitin-proteasome system (UPS) through NEDD4-1-mediated ubiquitination [102,103]. Involvement of PARK2 encoding ubiquitin E3 ligase Parkin in PTEN S-nitrosylation has been reported [104]. Depletion of PARK2 enhanced the 5-AMP-activated protein kinase (AMPK)-mediated activation of endothelial nitric oxide synthase (eNOS), leading to increases in NO levels that drove S-nitrosylation and subsequent ubiquitination of PTEN [100]. These findings suggest that the S-nitrosylation of PTEN could serve as a possible new therapeutic target.
4. Concluding remarks
The reversible oxidation of Cys residues in proteins upon cellular oxidants is linked to signaling events. PTEN was discovered as a bona fide tumor suppressor. The importance of its functions in the regulation of cell growth, motility, and the inhibition of apoptosis has been well-established. ROS has been recognized as a secondary messenger that can modify cell signaling by oxidizing protein cysteine thiols. Challenges have moved from PTEN pleiotropic natural functions toward understanding its regulation. This review concentrated on the redox regulation of PTEN, which is crucially linked to its tumor suppressor function.
Trx and Prx play vital roles in the control of intracellular redox state of PTEN. The participation of H2O2 in intracellular signaling by targeting PTEN, Trx, and Prx, and the regulation of H2O2 concentrations by Prx are depicted schematically in Fig. 7. Growth factors induced the activation of PI3K, resulting in the conversion of PIP2 to PIP3. PIP3 induced the production of H2O2 by activating the NOX (Nicotinamide adenine dinucleotide phosphate oxidase) complex. The interaction of Prx1 and PTEN is essential for protecting PTEN from oxidation-induced inactivation. PTEN lipid phosphatase activity was fully protected by Prx1 in cells under low H2O2 exposure, where Prx1 was found to bind PTEN as a monomer [75]. The generated H2O2 mediated the inactivation of cytosolic Prx molecules located nearby through forming intermolecular disulfides. The disulfides were subsequently and specifically reduced by Trx, which in turn received reducing equivalents from NADPH via TrxR. However, when treated with higher concentrations of H2O2, Prx1 is known to become irreversibly hyperoxidized and dissociate from PTEN. H2O2 can inactivate Prx in a two-step hyperoxidation of the active site Cys-SH to Cys-SO2H, which can be reactivated via an ATP-dependent reduction catalyzed by sulfiredoxin (Srx). Prx inactivation allows the accumulation of local H2O2, which in turn promotes the inactivation of PTEN by forming a disulfide bond. In addition to impaired activity of Prx, the intermolecular disulfide/dimerization of Trx also occurs, causing a loss of Trx reactivity, which in turn, promotes the oxidation of PTEN. This inactivation of PTEN increases the abundance of phosphorylated AKT and sufficiently triggers downstream signaling events. The impaired activity of Trx caused by dimerization provides a mechanism by which Trx activity is transiently inhibited under the conditions of oxidative stress, providing more time for sensing and transmission of oxidative signals. However, further studies are needed to reveal the mechanisms that involved in Trx transient inhibition and the important roles of Trx and Prx in redox signaling closely associated with PTEN redox regulation.
Declaration of competing interest
The author has no competing interests to declare.
Acknowledgments
The present study was supported by the grants (2018R1D1A1B06051438 and NRF-2015R1D1A1A01059571) from the National Research Foundation, Republic of Korea. Jiyoung Park was supported by the Health Fellowship Foundation.
References
- 1.Winterbourn C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008;4(5):278–286. doi: 10.1038/nchembio.85. [DOI] [PubMed] [Google Scholar]
- 2.Zhang L., Wang X., Cueto R., Effi C., Zhang Y., Tan H., Qin X., Ji Y., Yang X., Wang H. Biochemical basis and metabolic interplay of redox regulation. Redox Biol. 2019;26:101284. doi: 10.1016/j.redox.2019.101284. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rhee S.G., Kang S.W., Jeong W., Chang T.S., Yang K.S., Woo H.A. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr. Opin. Cell Biol. 2005;17(2):183–189. doi: 10.1016/j.ceb.2005.02.004. [DOI] [PubMed] [Google Scholar]
- 4.Rhee S.G., Chang T.S., Bae Y.S., Lee S.R., Kang S.W. Cellular regulation by hydrogen peroxide. J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.) 2003;14(8 Suppl 3):S211–S215. doi: 10.1097/01.asn.0000077404.45564.7e. [DOI] [PubMed] [Google Scholar]
- 5.Rhee S.G. Redox signaling: hydrogen peroxide as intracellular messenger. Exp. Mol. Med. 1999;31(2):53–59. doi: 10.1038/emm.1999.9. [DOI] [PubMed] [Google Scholar]
- 6.Corcoran A., Cotter T.G. Redox regulation of protein kinases. FEBS J. 2013;280(9):1944–1965. doi: 10.1111/febs.12224. [DOI] [PubMed] [Google Scholar]
- 7.Dean R.T., Fu S., Stocker R., Davies M.J. Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 1997;324(Pt 1):1–18. doi: 10.1042/bj3240001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Yan L.J., Sohal R.S. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc. Natl. Acad. Sci. U.S.A. 1998;95(22):12896–12901. doi: 10.1073/pnas.95.22.12896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Jones D.P. Redefining oxidative stress. Antioxidants Redox Signal. 2006;8(9–10):1865–1879. doi: 10.1089/ars.2006.8.1865. [DOI] [PubMed] [Google Scholar]
- 10.Roberts C.K., Sindhu K.K. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21–22):705–712. doi: 10.1016/j.lfs.2009.02.026. [DOI] [PubMed] [Google Scholar]
- 11.Finkel T. Oxygen radicals and signaling. Curr. Opin. Cell Biol. 1998;10(2):248–253. doi: 10.1016/s0955-0674(98)80147-6. [DOI] [PubMed] [Google Scholar]
- 12.Rhee S.G., Bae Y.S., Lee S.R., Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci. STKE : Signal Transduct. Knowl. Environ. 2000;53(2000):pe1. doi: 10.1126/stke.2000.53.pe1. [DOI] [PubMed] [Google Scholar]
- 13.Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 2000;279(6):L1005–L1028. doi: 10.1152/ajplung.2000.279.6.L1005. [DOI] [PubMed] [Google Scholar]
- 14.Kwon J., Lee S.R., Yang K.S., Ahn Y., Kim Y.J., Stadtman E.R., Rhee S.G. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. U.S.A. 2004;101(47):16419–16424. doi: 10.1073/pnas.0407396101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Lee S.R., Yang K.S., Kwon J., Lee C., Jeong W., Rhee S.G. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 2002;277(23):20336–20342. doi: 10.1074/jbc.M111899200. [DOI] [PubMed] [Google Scholar]
- 16.Sies H., Berndt C., Jones D.P. Oxidative stress. Annu. Rev. Biochem. 2017;86:715–748. doi: 10.1146/annurev-biochem-061516-045037. [DOI] [PubMed] [Google Scholar]
- 17.Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (New York, N.Y.) 1997;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
- 18.Funamoto S., Meili R., Lee S., Parry L., Firtel R.A. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell. 2002;109(5):611–623. doi: 10.1016/s0092-8674(02)00755-9. [DOI] [PubMed] [Google Scholar]
- 19.Maehama T., Taylor G.S., Dixon J.E. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 2001;70:247–279. doi: 10.1146/annurev.biochem.70.1.247. [DOI] [PubMed] [Google Scholar]
- 20.Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Canc. Cell. 2003;4(4):257–262. doi: 10.1016/s1535-6108(03)00248-4. [DOI] [PubMed] [Google Scholar]
- 21.Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95(1):29–39. doi: 10.1016/s0092-8674(00)81780-8. [DOI] [PubMed] [Google Scholar]
- 22.Okumura K., Mendoza M., Bachoo R.M., DePinho R.A., Cavenee W.K., Furnari F.B. PCAF modulates PTEN activity. J. Biol. Chem. 2006;281(36):26562–26568. doi: 10.1074/jbc.M605391200. [DOI] [PubMed] [Google Scholar]
- 23.Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (New York, N.Y.) 1998;280(5369):1614–1617. doi: 10.1126/science.280.5369.1614. [DOI] [PubMed] [Google Scholar]
- 24.Gu J., Tamura M., Pankov R., Danen E.H., Takino T., Matsumoto K., Yamada K.M. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 1999;146(2):389–403. doi: 10.1083/jcb.146.2.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Shi Y., Wang J., Chandarlapaty S., Cross J., Thompson C., Rosen N., Jiang X. PTEN is a protein tyrosine phosphatase for IRS1. Nat. Struct. Mol. Biol. 2014;21(6):522–527. doi: 10.1038/nsmb.2828. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Shnitsar I., Bashkurov M., Masson G.R., Ogunjimi A.A., Mosessian S., Cabeza E.A., Hirsch C.L., Trcka D., Gish G., Jiao J., Wu H., Winklbauer R., Williams R.L., Pelletier L., Wrana J.L., Barrios-Rodiles M. PTEN regulates cilia through Dishevelled. Nat. Commun. 2015;6:8388. doi: 10.1038/ncomms9388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Gu T., Zhang Z., Wang J., Guo J., Shen W.H., Yin Y. CREB is a novel nuclear target of PTEN phosphatase. Canc. Res. 2011;71(8):2821–2825. doi: 10.1158/0008-5472.CAN-10-3399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor, Nature reviews. Mol. Cell Biol. 2012;13(5):283–296. doi: 10.1038/nrm3330. [DOI] [PubMed] [Google Scholar]
- 29.Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008;27(41):5477–5485. doi: 10.1038/onc.2008.248. [DOI] [PubMed] [Google Scholar]
- 30.Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403–414. doi: 10.1016/j.cell.2008.04.013. [DOI] [PubMed] [Google Scholar]
- 31.Raftopoulou M., Etienne-Manneville S., Self A., Nicholls S., Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science (New York, N.Y.) 2004;303(5661):1179–1181. doi: 10.1126/science.1092089. [DOI] [PubMed] [Google Scholar]
- 32.Okumura K., Zhao M., Depinho R.A., Furnari F.B., Cavenee W.K. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 2005;102(8):2703–2706. doi: 10.1073/pnas.0409370102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Zhao D., Lu X., Wang G., Lan Z., Liao W., Li J., Liang X., Chen J.R., Shah S., Shang X., Tang M., Deng P., Dey P., Chakravarti D., Chen P., Spring D.J., Navone N.M., Troncoso P., Zhang J., Wang Y.A., DePinho R.A. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017;542(7642):484–488. doi: 10.1038/nature21357. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Blanco-Aparicio C., Renner O., Leal J.F., Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28(7):1379–1386. doi: 10.1093/carcin/bgm052. [DOI] [PubMed] [Google Scholar]
- 35.Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., McNutt M.A., Shen W.H., Yin Y. PTENalpha, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metabol. 2014;19(5):836–848. doi: 10.1016/j.cmet.2014.03.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Wang L., Cho Y.L., Tang Y., Wang J., Park J.E., Wu Y., Wang C., Tong Y., Chawla R., Zhang J., Shi Y., Deng S., Lu G., Wu Y., Tan H.W., Pawijit P., Lim G.G., Chan H.Y., Zhang J., Fang L., Yu H., Liou Y.C., Karthik M., Bay B.H., Lim K.L., Sze S.K., Yap C.T., Shen H.M. PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy. Cell Res. 2018;28(8):787–802. doi: 10.1038/s41422-018-0056-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Liang H., Chen X., Yin Q., Ruan D., Zhao X., Zhang C., McNutt M.A., Yin Y. PTENbeta is an alternatively translated isoform of PTEN that regulates rDNA transcription. Nat. Commun. 2017;8:14771. doi: 10.1038/ncomms14771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell. 2000;100(4):387–390. doi: 10.1016/s0092-8674(00)80674-1. [DOI] [PubMed] [Google Scholar]
- 39.Lee Y.R., Chen M., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat. Rev. Mol. Cell Biol. 2018;19(9):547–562. doi: 10.1038/s41580-018-0015-0. [DOI] [PubMed] [Google Scholar]
- 40.Papa A., Wan L., Bonora M., Salmena L., Song M.S., Hobbs R.M., Lunardi A., Webster K., Ng C., Newton R.H., Knoblauch N., Guarnerio J., Ito K., Turka L.A., Beck A.H., Pinton P., Bronson R.T., Wei W., Pandolfi P.P. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell. 2014;157(3):595–610. doi: 10.1016/j.cell.2014.03.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Liu X., Wang L., Cai J., Liu K., Liu M., Wang H., Zhang H. N-acetylcysteine alleviates H2O2-induced damage via regulating the redox status of intracellular antioxidants in H9c2 cells. Int. J. Mol. Med. 2019;43(1):199–208. doi: 10.3892/ijmm.2018.3962. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Han S.J., Ahn Y., Park I., Zhang Y., Kim I., Kim H.W., Ku C.S., Chay K.O., Yang S.Y., Ahn B.W., Jang D.I., Lee S.R. Assay of the redox state of the tumor suppressor PTEN by mobility shift. Methods (San Diego, Calif.) 2015;77–78:58–62. doi: 10.1016/j.ymeth.2015.01.007. [DOI] [PubMed] [Google Scholar]
- 43.Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. U.S.A. 1998;95(23):13513–13518. doi: 10.1073/pnas.95.23.13513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Leslie N.R. The redox regulation of PI 3-kinase-dependent signaling. Antioxidants Redox Signal. 2006;8(9–10):1765–1774. doi: 10.1089/ars.2006.8.1765. [DOI] [PubMed] [Google Scholar]
- 45.Leslie N.R., Bennett D., Lindsay Y.E., Stewart H., Gray A., Downes C.P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003;22(20):5501–5510. doi: 10.1093/emboj/cdg513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Holmgren A. Thioredoxin. Annu. Rev. Biochem. 1985;54:237–271. doi: 10.1146/annurev.bi.54.070185.001321. [DOI] [PubMed] [Google Scholar]
- 47.Collet J.F., Messens J. Structure, function, and mechanism of thioredoxin proteins. Antioxidants Redox Signal. 2010;13(8):1205–1216. doi: 10.1089/ars.2010.3114. [DOI] [PubMed] [Google Scholar]
- 48.Koharyova M., Kollarova M. Thioredoxin system - a novel therapeutic target. Gen. Physiol. Biophys. 2015;34(3):221–233. doi: 10.4149/gpb_2015006. [DOI] [PubMed] [Google Scholar]
- 49.Han S.J., Zhang Y., Kim I., Chay K.O., Yoon H.J., Jang D.I., Yang S.Y., Park J., Woo H.A., Park I., Lee S.R. Redox regulation of the tumor suppressor PTEN by the thioredoxin system and cumene hydroperoxide. Free Radical Biol. Med. 2017;112:277–286. doi: 10.1016/j.freeradbiomed.2017.07.029. [DOI] [PubMed] [Google Scholar]
- 50.Weichsel A., Gasdaska J.R., Powis G., Montfort W.R. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure (London, England:1993. 1996;4(6):735–751. doi: 10.1016/s0969-2126(96)00079-2. [DOI] [PubMed] [Google Scholar]
- 51.Hwang J., Nguyen L.T., Jeon Y.H., Lee C.Y., Kim M.H. Crystal structure of fully oxidized human thioredoxin. Biochem. Biophys. Res. Commun. 2015;467(2):218–222. doi: 10.1016/j.bbrc.2015.10.003. [DOI] [PubMed] [Google Scholar]
- 52.Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J. Biol. Chem. 1979;254(19):9627–9632. [PubMed] [Google Scholar]
- 53.Watson W.H., Pohl J., Montfort W.R., Stuchlik O., Reed M.S., Powis G., Jones D.P. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J. Biol. Chem. 2003;278(35):33408–33415. doi: 10.1074/jbc.M211107200. [DOI] [PubMed] [Google Scholar]
- 54.Hashemy S.I., Holmgren A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J. Biol. Chem. 2008;283(32):21890–21898. doi: 10.1074/jbc.M801047200. [DOI] [PubMed] [Google Scholar]
- 55.Fritz-Wolf K., Kehr S., Stumpf M., Rahlfs S., Becker K. Crystal structure of the human thioredoxin reductase-thioredoxin complex. Nat. Commun. 2011;2:383. doi: 10.1038/ncomms1382. [DOI] [PubMed] [Google Scholar]
- 56.Powis G., Kirkpatrick D.L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007;7(4):392–397. doi: 10.1016/j.coph.2007.04.003. [DOI] [PubMed] [Google Scholar]
- 57.Zhang Y., Han S.J., Park I., Kim I., Chay K.O., Kim S.M., Jang D.I., Lee T.H., Lee S.R. Redox regulation of the tumor suppressor PTEN by hydrogen peroxide and tert-butyl hydroperoxide. Int. J. Mol. Sci. 2017;18(5) doi: 10.3390/ijms18050982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Grogan T.M., Fenoglio-Prieser C., Zeheb R., Bellamy W., Frutiger Y., Vela E., Stemmerman G., Macdonald J., Richter L., Gallegos A., Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol. 2000;31(4):475–481. doi: 10.1053/hp.2000.6546. [DOI] [PubMed] [Google Scholar]
- 59.Raffel J., Bhattacharyya A.K., Gallegos A., Cui H., Einspahr J.G., Alberts D.S., Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 2003;142(1):46–51. doi: 10.1016/S0022-2143(03)00068-4. [DOI] [PubMed] [Google Scholar]
- 60.Meuillet E.J., Mahadevan D., Berggren M., Coon A., Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch. Biochem. Biophys. 2004;429(2):123–133. doi: 10.1016/j.abb.2004.04.020. [DOI] [PubMed] [Google Scholar]
- 61.Lee S., Kim S.M., Lee R.T. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxidants Redox Signal. 2013;18(10):1165–1207. doi: 10.1089/ars.2011.4322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Rhee S.G., Kang S.W., Chang T.S., Jeong W., Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life. 2001;52(1–2):35–41. doi: 10.1080/15216540252774748. [DOI] [PubMed] [Google Scholar]
- 63.Rhee S.G. Cell signaling. H2O2, a necessary evil for cell signaling. Science (New York, N.Y.) 2006;312(5782):1882–1883. doi: 10.1126/science.1130481. [DOI] [PubMed] [Google Scholar]
- 64.Chae H.Z., Uhm T.B., Rhee S.G. Dimerization of thiol-specific antioxidant and the essential role of cysteine 47. Proc. Natl. Acad. Sci. U.S.A. 1994;91(15):7022–7026. doi: 10.1073/pnas.91.15.7022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Yang K.S., Kang S.W., Woo H.A., Hwang S.C., Chae H.Z., Kim K., Rhee S.G. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. J. Biol. Chem. 2002;277(41):38029–38036. doi: 10.1074/jbc.M206626200. [DOI] [PubMed] [Google Scholar]
- 66.Chang T.S., Jeong W., Woo H.A., Lee S.M., Park S., Rhee S.G. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J. Biol. Chem. 2004;279(49):50994–51001. doi: 10.1074/jbc.M409482200. [DOI] [PubMed] [Google Scholar]
- 67.Jang H.H., Lee K.O., Chi Y.H., Jung B.G., Park S.K., Park J.H., Lee J.R., Lee S.S., Moon J.C., Yun J.W., Choi Y.O., Kim W.Y., Kang J.S., Cheong G.W., Yun D.J., Rhee S.G., Cho M.J., Lee S.Y. Two enzymes in one; two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell. 2004;117(5):625–635. doi: 10.1016/j.cell.2004.05.002. [DOI] [PubMed] [Google Scholar]
- 68.Lim J.C., Choi H.I., Park Y.S., Nam H.W., Woo H.A., Kwon K.S., Kim Y.S., Rhee S.G., Kim K., Chae H.Z. Irreversible oxidation of the active-site cysteine of peroxiredoxin to cysteine sulfonic acid for enhanced molecular chaperone activity. J. Biol. Chem. 2008;283(43):28873–28880. doi: 10.1074/jbc.M804087200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Rhee S.G., Jeong W., Chang T.S., Woo H.A. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int. 2007;Supplement(106):S3–S8. doi: 10.1038/sj.ki.5002380. [DOI] [PubMed] [Google Scholar]
- 70.Woo H.A., Yim S.H., Shin D.H., Kang D., Yu D.Y., Rhee S.G. Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell. 2010;140(4):517–528. doi: 10.1016/j.cell.2010.01.009. [DOI] [PubMed] [Google Scholar]
- 71.Chang T.S., Jeong W., Choi S.Y., Yu S., Kang S.W., Rhee S.G. Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. J. Biol. Chem. 2002;277(28):25370–25376. doi: 10.1074/jbc.M110432200. [DOI] [PubMed] [Google Scholar]
- 72.Parmigiani R.B., Xu W.S., Venta-Perez G., Erdjument-Bromage H., Yaneva M., Tempst P., Marks P.A. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl. Acad. Sci. U.S.A. 2008;105(28):9633–9638. doi: 10.1073/pnas.0803749105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Park J.W., Mieyal J.J., Rhee S.G., Chock P.B. Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J. Biol. Chem. 2009;284(35):23364–23374. doi: 10.1074/jbc.M109.021394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Fang J., Nakamura T., Cho D.H., Gu Z., Lipton S.A. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2007;104(47):18742–18747. doi: 10.1073/pnas.0705904104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Cao J., Schulte J., Knight A., Leslie N.R., Zagozdzon A., Bronson R., Manevich Y., Beeson C., Neumann C.A. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 2009;28(10):1505–1517. doi: 10.1038/emboj.2009.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Kim S.C., Lee J.R., Park S.J. Role of 6-shogaol in tert -butyl hydroperoxide-induced apoptosis of HepG2 cells. Pharmacology. 2014;93(3–4):137–144. doi: 10.1159/000360090. [DOI] [PubMed] [Google Scholar]
- 77.Guyton K.Z., Gorospe M., Kensler T.W., Holbrook N.J. Mitogen-activated protein kinase (MAPK) activation by butylated hydroxytoluene hydroperoxide: implications for cellular survival and tumor promotion. Canc. Res. 1996;56(15):3480–3485. [PubMed] [Google Scholar]
- 78.Kasai H., Kawai K. DNA methylation at the C-5 position of cytosine by methyl radicals: a possible role for epigenetic change during carcinogenesis by environmental agents. Chem. Res. Toxicol. 2009;22(6):984–989. doi: 10.1021/tx900099s. [DOI] [PubMed] [Google Scholar]
- 79.Cerutti P.A. Prooxidant states and tumor promotion. Science (New York, N.Y.) 1985;227(4685):375–381. doi: 10.1126/science.2981433. [DOI] [PubMed] [Google Scholar]
- 80.Taffe B.G., Takahashi N., Kensler T.W., Mason R.P. Generation of free radicals from organic hydroperoxide tumor promoters in isolated mouse keratinocytes. Formation of alkyl and alkoxyl radicals from tert-butyl hydroperoxide and cumene hydroperoxide. J. Biol. Chem. 1987;262(25):12143–12149. [PubMed] [Google Scholar]
- 81.Gogvadze V.G., Zhukova A.A. The role of lipid peroxidation products in cumene hydroperoxide-induced Ca2+ efflux from mitochondria. FEBS Lett. 1991;287(1–2):139–141. doi: 10.1016/0014-5793(91)80034-z. [DOI] [PubMed] [Google Scholar]
- 82.Ayala A., Munoz M.F., Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014;2014:360438. doi: 10.1155/2014/360438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Rush G.F., Gorski J.R., Ripple M.G., Sowinski J., Bugelski P., Hewitt W.R. Organic hydroperoxide-induced lipid peroxidation and cell death in isolated hepatocytes. Toxicol. Appl. Pharmacol. 1985;78(3):473–483. doi: 10.1016/0041-008x(85)90255-8. [DOI] [PubMed] [Google Scholar]
- 84.Ayala A., Parrado J., Bougria M., Machado A. Effect of oxidative stress, produced by cumene hydroperoxide, on the various steps of protein synthesis. Modifications of elongation factor-2. J. Biol. Chem. 1996;271(38):23105–23110. doi: 10.1074/jbc.271.38.23105. [DOI] [PubMed] [Google Scholar]
- 85.Hix S., Kadiiska M.B., Mason R.P., Augusto O. In vivo metabolism of tert-butyl hydroperoxide to methyl radicals. EPR spin-trapping and DNA methylation studies. Chem. Res. Toxicol. 2000;13(10):1056–1064. doi: 10.1021/tx000130l. [DOI] [PubMed] [Google Scholar]
- 86.Chance B., Sies H., Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979;59(3):527–605. doi: 10.1152/physrev.1979.59.3.527. [DOI] [PubMed] [Google Scholar]
- 87.Masaki N., Kyle M.E., Farber J.L. tert-butyl hydroperoxide kills cultured hepatocytes by peroxidizing membrane lipids. Arch. Biochem. Biophys. 1989;269(2):390–399. doi: 10.1016/0003-9861(89)90122-7. [DOI] [PubMed] [Google Scholar]
- 88.Rice-Evans C., Baysal E., Pashby D.P., Hochstein P. t-butyl hydroperoxide-induced perturbations of human erythrocytes as a model for oxidant stress. Biochim. Biophys. Acta. 1985;815(3):426–432. doi: 10.1016/0005-2736(85)90370-0. [DOI] [PubMed] [Google Scholar]
- 89.Castilho R.F., Kowaltowski A.J., Meinicke A.R., Bechara E.J., Vercesi A.E. Permeabilization of the inner mitochondrial membrane by Ca2+ ions is stimulated by t-butyl hydroperoxide and mediated by reactive oxygen species generated by mitochondria. Free Radical Biol. Med. 1995;18(3):479–486. doi: 10.1016/0891-5849(94)00166-h. [DOI] [PubMed] [Google Scholar]
- 90.Guidarelli A., Clementi E., Brambilla L., Cantoni O. Mechanism of the antimycin A-mediated enhancement of t-butylhydroperoxide-induced single-strand breakage in DNA. Biochem. J. 1997;328(Pt 3):801–806. doi: 10.1042/bj3280801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Guidarelli A., Cattabeni F., Cantoni O. Alternative mechanisms for hydroperoxide-induced DNA single strand breakage. Free Radic. Res. 1997;26(6):537–547. doi: 10.3109/10715769709097825. [DOI] [PubMed] [Google Scholar]
- 92.Klil-Drori A.J., Ariel A. 15-Lipoxygenases in cancer: a double-edged sword? Prostag. Other Lipid Mediat. 2013;106:16–22. doi: 10.1016/j.prostaglandins.2013.07.006. [DOI] [PubMed] [Google Scholar]
- 93.Middleton M.K., Zukas A.M., Rubinstein T., Jacob M., Zhu P., Zhao L., Blair I., Pure E. Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. J. Exp. Med. 2006;203(11):2529–2540. doi: 10.1084/jem.20061444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Mahipal S.V., Subhashini J., Reddy M.C., Reddy M.M., Anilkumar K., Roy K.R., Reddy G.V., Reddanna P. Effect of 15-lipoxygenase metabolites, 15-(S)-HPETE and 15-(S)-HETE on chronic myelogenous leukemia cell line K-562: reactive oxygen species (ROS) mediate caspase-dependent apoptosis. Biochem. Pharmacol. 2007;74(2):202–214. doi: 10.1016/j.bcp.2007.04.005. [DOI] [PubMed] [Google Scholar]
- 95.Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 2009;8(7):579–591. doi: 10.1038/nrd2803. [DOI] [PubMed] [Google Scholar]
- 96.Conrad M., Sandin A., Forster H., Seiler A., Frijhoff J., Dagnell M., Bornkamm G.W., Radmark O., Hooft van Huijsduijnen R., Aspenstrom P., Bohmer F., Ostman A. 12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases. Proc. Natl. Acad. Sci. U.S.A. 2010;107(36):15774–15779. doi: 10.1073/pnas.1007909107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Covey T.M., Edes K., Fitzpatrick F.A. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene. 2007;26(39):5784–5792. doi: 10.1038/sj.onc.1210391. [DOI] [PubMed] [Google Scholar]
- 98.Zhang Y., Park J., Han S.J., Lim Y., Park I., Kim J.S., Woo H.A., Lee S.R. Peroxiredoxin III protects tumor suppressor PTEN from oxidation by 15-Hydroperoxy-eicosatetraenoic acid. Oxid. Med. Cell. Longev. 2019;2019:2828493. doi: 10.1155/2019/2828493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Yu C.X., Li S., Whorton A.R. Redox regulation of PTEN by S-nitrosothiols. Mol. Pharmacol. 2005;68(3):847–854. doi: 10.1124/mol.104.010504. [DOI] [PubMed] [Google Scholar]
- 100.Gupta A., Anjomani-Virmouni S., Koundouros N., Dimitriadi M., Choo-Wing R., Valle A., Zheng Y., Chiu Y.H., Agnihotri S., Zadeh G., Asara J.M., Anastasiou D., Arends M.J., Cantley L.C., Poulogiannis G. PARK2 depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-nitrosylation. Mol. Cell. 2017;65(6):999–1013. doi: 10.1016/j.molcel.2017.02.019. e7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Zhu L., Li L., Zhang Q., Yang X., Zou Z., Hao B., Marincola F.M., Liu Z., Zhong Z., Wang M., Li X., Wang Q., Li K., Gao W., Yao K., Liu Q. NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells. Cell Death Discov. 2017;3:17011. doi: 10.1038/cddiscovery.2017.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Kwak Y.D., Ma T., Diao S., Zhang X., Chen Y., Hsu J., Lipton S.A., Masliah E., Xu H., Liao F.F. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol. Neurodegener. 2010;5:49. doi: 10.1186/1750-1326-5-49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Numajiri N., Takasawa K., Nishiya T., Tanaka H., Ohno K., Hayakawa W., Asada M., Matsuda H., Azumi K., Kamata H., Nakamura T., Hara H., Minami M., Lipton S.A., Uehara T. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN) Proc. Natl. Acad. Sci. U.S.A. 2011;108(25):10349–10354. doi: 10.1073/pnas.1103503108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Gupta A., Anjomani-Virmouni S., Koundouros N., Poulogiannis G. PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN. Mol. Cell. Oncol. 2017;4(6) doi: 10.1080/23723556.2017.1329692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Putz U., Mah S., Goh C.P., Low L.H., Howitt J., Tan S.S. PTEN secretion in exosomes. Methods (San Diego, Calif.) 2015;77–78:157–163. doi: 10.1016/j.ymeth.2014.12.016. [DOI] [PubMed] [Google Scholar]